Sarepta Therapeutics (SRPT) Free Cash Flow (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Free Cash Flow of -$204.8 million for Q1 2026, up 67.35% year-over-year from -$122.4 million in Q1 2025, and down 260.45% quarter-over-quarter from $127.6 million in Q4 2025.
Sarepta Therapeutics (SRPT) Free Cash Flow (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$204.8 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 67.35% year-over-year to -$204.8 million; the TTM figure through Mar 2026 stood at $114.9 million (up 116.52% YoY), while the FY2025 annual figure was -$307.5 million, up 10.3% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$204.8 million, down from $127.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $229.5 million in Q2 2025, with the low at -$627.1 million in Q1 2025.
- The 5-year median for Free Cash Flow is -$100.4 million (2022), against an average of -$105.2 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow plunged 218.27% in 2022, then jumped 1713.64% in 2025.
- Sarepta Therapeutics' Free Cash Flow stood at -$100.4 million in 2022, then increased by 26.57% to -$73.7 million in 2023, then jumped by 173.23% to $54.0 million in 2024, then soared by 136.48% to $127.6 million in 2025, then plunged by 260.45% to -$204.8 million in 2026.
- Business Quant data shows SRPT's Free Cash Flow at -$204.8 million in Q1 2026, $127.6 million in Q4 2025, and -$37.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 196.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 196.52 Mn |
| Jun 30, 2026 | 196.52 Mn |
| Mar 31, 2026 | -204.76 Mn |
| Mar 31, 2026 | -204.76 Mn |
| Dec 31, 2025 | 127.62 Mn |
| Dec 31, 2025 | 127.62 Mn |
| Sep 30, 2025 | -37.52 Mn |
| Sep 30, 2025 | -37.52 Mn |
| Jun 30, 2025 | 229.54 Mn |
| Jun 30, 2025 | 229.54 Mn |
| Mar 31, 2025 | -627.09 Mn |
| Mar 31, 2025 | -627.09 Mn |
| Dec 31, 2024 | 53.96 Mn |
| Dec 31, 2024 | 53.96 Mn |
| Sep 30, 2024 | -107.96 Mn |
| Sep 30, 2024 | -107.96 Mn |
| Jun 30, 2024 | -14.23 Mn |
| Jun 30, 2024 | -14.23 Mn |
| Mar 31, 2024 | -274.52 Mn |
| Mar 31, 2024 | -274.52 Mn |